/SPRY

SPRY Stock - ARS Pharmaceuticals, Inc.

Q: What is the analyst price target for SPRY?

Analyst price target information is not currently available for SPRY.

Q: What is SPRY's market cap?

Market capitalization information is not currently available for SPRY.

Healthcare|Biotechnology|NASDAQ

$11.31-0.62%

$0.07 (-0.62%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+165.3%upside

Target: $30.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SPRY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.74

52W High$18.90

52W Low$6.66

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$89.15M	$30,000	$1.32M	$5.51M	$17.84M
Gross Profit	$68.59M	$30,000	$1.32M	$5.29M	$3.77M
Gross Margin	76.9%	100.0%	100.0%	96.1%	21.1%
Operating Income	$-3,083,000	$-67,520,000	$-35,516,000	$-19,454,000	$-469,000
Net Income	$8.00M	$-54,365,000	$-34,682,000	$-20,243,000	$-1,065,000
Net Margin	9.0%	-181216.7%	-2635.4%	-367.7%	-6.0%
EPS	$0.08	$-0.57	$-0.87	$-0.70	$-0.03

Company Overview

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Visit Website

Earnings History & Surprises

SPRY

Beat Rate

39%

Last 18 quarters

Avg Surprise

+110.8%

EPS vs Estimate

Beats / Misses

7/9

2 met exactly

Latest EPS

$-0.52

Q4 2025

EPS Surprise History

Q1 24

+50.0%

$-0.07vs$-0.14

Q2 24

0.0%

$-0.11vs$-0.11

Q3 24

-8.3%

$-0.13vs$-0.12

Q4 24

-11.1%

$-0.20vs$-0.18

Q1 25

+1400.0%

$0.52vs$-0.04

Q2 25

0.0%

$-0.35vs$-0.35

Q3 25

-12.2%

$-0.46vs$-0.41

Q4 25

-15.6%

$-0.52vs$-0.45

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 12, 2026	—	—	—	—
Q1 2026	Mar 19, 2026	$-0.40	—	—	—
Q4 2025	Nov 10, 2025	$-0.45	$-0.52	-15.6%	✗ MISS
Q3 2025	Aug 13, 2025	$-0.41	$-0.46	-12.2%	✗ MISS
Q2 2025	May 14, 2025	$-0.35	$-0.35	0.0%	= MET
Q1 2025	Mar 20, 2025	$-0.04	$0.52	+1400.0%	✓ BEAT
Q4 2024	Nov 13, 2024	$-0.18	$-0.20	-11.1%	✗ MISS
Q3 2024	Aug 6, 2024	$-0.12	$-0.13	-8.3%	✗ MISS
Q2 2024	May 9, 2024	$-0.11	$-0.11	0.0%	= MET
Q1 2024	Mar 21, 2024	$-0.14	$-0.07	+50.0%	✓ BEAT
Q4 2023	Nov 9, 2023	$-0.18	$-0.16	+11.1%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.17	$-0.18	-5.9%	✗ MISS
Q2 2023	May 15, 2023	$-0.17	$-0.16	+5.9%	✓ BEAT
Q1 2023	Mar 23, 2023	$-0.13	$0.77	+692.3%	✓ BEAT
Q4 2022	Nov 2, 2022	$-0.35	$-0.50	-42.9%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.48	$-0.55	-14.6%	✗ MISS
Q2 2022	May 12, 2022	$-0.54	$-0.70	-29.6%	✗ MISS
Q1 2022	Mar 31, 2022	$-0.70	$-0.67	+4.3%	✓ BEAT
Q4 2021	Nov 10, 2021	$-0.67	$-0.65	+3.0%	✓ BEAT
Q3 2021	Aug 12, 2021	$-0.53	$-0.70	-32.1%	✗ MISS

Frequently Asked Questions about SPRY

What is SPRY's current stock price?

ARS Pharmaceuticals, Inc. (SPRY) is currently trading at $11.31 per share. The stock has moved -0.62% today.

What is the analyst price target for SPRY?

The average analyst price target for SPRY is $30.00, based on 1 analyst.

What sector is ARS Pharmaceuticals, Inc. in?

ARS Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is SPRY's market cap?

ARS Pharmaceuticals, Inc. has a market capitalization of $1.11 billion, making it a small-cap company.

Does SPRY pay dividends?

No, ARS Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.